Dossier
Catalyst Pharmaceuticals
Coverage of Catalyst Pharmaceuticals in the Nexus archive.
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
Angelini Pharma is buying Catalyst Pharmaceuticals for $4.1 billion in cash, valuing the company at $31.50 a share. This deal gives Angelini a foothold in the US market and expands its work in neurology. The acquisition includes three approved rare disease medicines.